A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 Years of Age) With Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 Years of Age) With Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively
Inclusion Criteria
- Participants must have completed the double-blind treatment period (ie, Visit 8) of Study CN0120020 or the double-blind treatment period (ie, Week 8) of Study CN0120044 or CN0120045, without an adverse event (AE) that, in the investigator's opinion, may indicate an unacceptable safety risk.
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Ciudad Autónoma de Buenos Aires, Buenos Aires C1133AAH, Argentina
Gdansk, 80-546, Germany
Bunkyo-ku, Tokyo 113-8431, Japan
Yokohama, Kanagawa, 213-8507, Japan
Cluj-Napoca, 400370, Romania
714-999-6688
909-488-9116
424-227-8127
407-423-7149
404-881-5800
773-620-2995
+81-11-771-5660